EazeBio
Rapid biomarker tests read by a phone or a clinic reader, and the software that tracks them over time.
- FDA device listings
- 7 active · Class I
- Two assay formats
- Lateral flow at home · fluorescent immunoassay in clinic
- Peer-reviewed
- Two 2026 Journal of Fluorescence papers
- Co-development
- Cortisol biosensor with UC Santa Cruz
Overview
A Livermore biosensing company with seven active FDA device listings and two 2026 papers, opening to clinics first and to individuals through early access.
EazeBio Inc. is a Livermore, California company that builds rapid biomarker tests and the software that reads them over time. The same assay chemistry runs two ways: a lateral-flow cassette read by a smartphone camera for wellness screening at home, and a fluorescent immunoassay on a dedicated reader for clinics and laboratories. The professional line carries seven active FDA device listings, its assay work is published in the Journal of Fluorescence, and it is co-developing a cortisol biosensor with UC Santa Cruz.
At a glance
Which assay format fits the setting, and how far along each line is.
- Samples and timing
- Fingerstick, saliva or urine · about 15 minutes
- Access today
- Clinical overview for professionals · early-access list for individualsClinical overview
- FDA device listings
- FSH, LH, prolactin, insulin and estradiol fluorescent immunoassays, listed 26 and 29 June 2026 under FEI 3047746876
- Two assay formats
- Lateral flow at home · fluorescent immunoassay in clinic
- Peer-reviewed
- Two 2026 Journal of Fluorescence papers
Pricing
Services
Clinical and laboratory
Clinical and laboratory panels
Pilots, partnerships and research collaboration
Consumer wellness screening
Eaze Panel wellness panels
Single-analyte test kits
Food and water screening
Clean Plate
Safe Sip
Offerings
- Clinical and laboratory panelsContact for pricing
For professionals
Fluorescent immunoassays on a dedicated reader for clinics and laboratories, compatible with LDT-style workflows, scoped through a clinical overview with the EazeBio team
Panel scope, reader, sample types, throughput, output format and the regulatory basis for your setting are agreed in the overview.
Request a clinical overviewLink verifiedServiceConsultation
- Pilots, partnerships and research collaborationContact for pricing
For professionals
Clinical pilots, platform partnerships, preventive programs and research collaboration, scoped to the markers and care pathway a partner runs
Contact the EazeBio teamLink verifiedServiceProfessional Service
- Clean Plate and Safe Sip panelsPrice not published
For consumersWaitlist
Clean Plate screens food for Staph toxin SEB, Salmonella, E. coli O157, Campylobacter and Norovirus; Safe Sip screens water for E. coli, Giardia, Cryptosporidium and V. cholerae, both in 15 minutes
Both run on the EazeBio smartphone reader, from a food rinsate, surface swab or filtered water concentrate.
Join the food and water early-access listLink verifiedProductTest
Clinics and laboratories: terms are scoped in a clinical overview covering panel scope, reader, workflow fit and the applicable regulatory basis.
Individuals: the Eaze Panel wellness panels, single-analyte kits and the Clean Plate and Safe Sip food and water panels open through an early-access list, which EazeBio says carries early-access pricing.
Prices checked 23 Sep 2026
Availability
Diagnostics
At home
EazeBio
Seven symptom-led at-home panels, among them Always Tired (ferritin, B12, vitamin D, TSH, HbA1c) and Stressed & Inflamed (cortisol, hs-CRP, GDF-15), plus a build-your-own option across 21 biomarkers; launching through a waitlist, price not yet published
Diagnostic programs
EazeBio
Seven one-marker kits: Prolactin, LH, FSH, AMH and Estradiol (E2) in FIA format, plus an Ovulation LH kit and an FSH (Menopause) kit; waitlist, price not yet published
Leadership and science team
The people who sign EazeBio's published assay work also run the company.
Reem Mahrat
Founder and Chief Executive Officer
First author on the 2026 Tau441 paper and corresponding author on the 2026 cortisol paper.
Ying Chen, PhD, MBA
Co-founder and Chief Scientific Officer
Co-author on both 2026 Journal of Fluorescence papers.
Sulatha Dwarakanath, PhD
Chief Strategy Officer
Bill Howelle, MD, PhD
Chief Medical Officer
Kevin Seltzer, JD, CPA
Chief Financial Officer
Isam Alyousfir
Chief Information Officer
Aditi Malu, PhD
Vice President of R&D
Binh Lu
Head of Manufacturing
John Bruno, PhD
Advisor
Co-author on both 2026 papers and first author on the cortisol assay.
Evidence and limitations
How it works
EazeBio treats a test result as one input to a personal baseline. Samples from a fingerstick, saliva or urine run on the same chemistry at home or in clinic, and the digital layer normalizes the results and reports directional change over weeks and months rather than a single threshold crossing. The company says the layer is built to support clinical reasoning, not replace it.
Distinguishing details
- Checkable registrations. Seven active FDA device listings across five markers, verifiable in the FDA's own database.
- Published assay work. Two 2026 Journal of Fluorescence papers on cortisol and Tau441 assays, authored by its own team.
- One chemistry, two settings. The phone-read cassette and the clinic reader share the same interpretive framework.
- University co-development. An instrument-free cortisol biosensor with UC Santa Cruz, reported independently by SelectScience.
What to consider
- For clinics: bring the markers your pathway already orders, and ask about the reader, accepted sample types, throughput and output format.
- For individuals: the consumer panels open through early access; registering names the markers and setting you care about.
- Reading results: EazeBio positions its consumer kits as wellness screening tools and asks that results be reviewed with a healthcare provider.
Frequently asked questions
Evidence and how to read it
The seven FDA device listings were confirmed in the FDA's device registration and listing database on 23 September 2026, and all seven product codes (CGJ, CEP, CFT, CFP, CHP, NGE, NGA) sit in class I with a 510(k)-exempt submission type. A device listing is the registration record a manufacturer files for a product in its class.
Both 2026 papers carry EazeBio's chief executive, chief scientific officer and an advisor as authors, so they are the company's own published work. The Tau441 paper describes itself as preliminary development, and its performance figures describe serum in a laboratory setting.
Published work
Journal of Fluorescence · 27 June 2026
Bruno JG, Chen Y, Mahrat R
Journal of Fluorescence · 9 September 2026
Mahrat R, Chen Y, Bruno JG and co-authors
SelectScience · independent reporting
Transparency and sources
Identity, product lines and access routes, FDA registration and classification, publications, collaborations and team
Researched by Longevity.io from EazeBio's own pages, the FDA device databases, Crossref-confirmed publications and SelectScience. No commercial relationship with EazeBio.
Reviewed
Company site
- Official site
- Platform
- Professional route
- Panels
- Kits
- Food and water
- Company
- Contact
Independent registers, publications and reporting
- Regulatory register
- Regulatory register
- Peer-reviewed paper
- Peer-reviewed paper
- Independent reporting
Trust
Registration
US Food and Drug Administration · device registration and listing
Seven active device listings under registrant EAZEBIO (FEI 3047746876) for FSH, LH, prolactin, insulin and estradiol fluorescent immunoassays, all in device class I with a 510(k)-exempt submission type. A listing is the registration record a manufacturer files for a product in its class.
FDA device registration and listing, FEI 3047746876
Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.
Keep exploring
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint